靶向疗法的出现彻底改变了晚期癌基因驱动的非小细胞肺癌（NSCLC）的治疗。尽管如此，尽管最初反应显着，但耐药性的发展是不可避免的。尽管已经描述了获得性耐药的潜在机制，例如靶向突变、旁路途径或谱系转化，但克服耐药性仍然具有挑战性。最近的证据表明，耐药持续细胞（DTP）是对初始药物暴露具有耐受性的肿瘤细胞，会产生获得耐药性的细胞。因此，正在研究通过靶向DTP细胞来根除癌症的可能性，并提出了各种策略。在此，我们回顾了 DTP 细胞的总体特征、当前定义 DTP 标记物的努力，以及在癌基因驱动的 NSCLC 中靶向和根除 DTP 细胞的潜在治疗策略。我们还讨论了该领域未来的挑战。版权所有 © 2024 Elsevier B.V. 保留所有权利。

The advent of targeted therapies revolutionized treatments of advanced oncogene-driven non-small cell lung cancer (NSCLC). Nonetheless, despite initial dramatic responses, development of drug resistance is inevitable. Although mechanisms underlying acquired resistance, such as on-target mutations, bypass pathways, or lineage transformation, have been described, overcoming drug resistance remains challenging. Recent evidence suggests that drug-tolerant persister (DTP) cells, which are tumor cells tolerant to initial drug exposure, give rise to cells that acquire drug resistance. Thus, the possibility of eradicating cancer by targeting DTP cells is under investigation, and various strategies are proposed. Here, we review overall features of DTP cells, current efforts to define DTP markers, and potential therapeutic strategies to target and eradicate DTP cells in oncogene-driven NSCLC. We also discuss future challenges in the field.Copyright © 2024 Elsevier B.V. All rights reserved.